Integrase-RNA interactions underscore the critical role of integrase in HIV-1 virion morphogenesis

  1. Jennifer L Elliott
  2. Jenna Eve Eschbach
  3. Pratibha C Koneru
  4. Wen Li
  5. Maritza Puray Chavez
  6. Dana Townsend
  7. Dana Q Lawson
  8. Alan N Engelman
  9. Mamuka Kvaratskhelia
  10. Sebla Bulent Kutluay  Is a corresponding author
  1. Washington University School of Medicine, United States
  2. University of Colorado School of Medicine, United States
  3. Department of Cancer Immunology and Virology, United States
  4. Dana-Farber Cancer Institute, United States

Abstract

A number of human immunodeficiency virus 1 integrase (IN) alterations, referred to as class II substitutions, exhibit pleotropic effects during virus replication. However, the underlying mechanism for the class II phenotype is not known. Here we demonstrate that all tested class II IN substitutions compromised IN-RNA binding in virions by one of three distinct mechanisms: i) markedly reducing IN levels thus precluding formation of IN complexes with viral RNA; ii) adversely affecting functional IN multimerization and consequently impairing IN binding to viral RNA; iii) directly compromising IN-RNA interactions without substantially affecting IN levels or functional IN multimerization. Inhibition of IN-RNA interactions resulted in mislocalization of the viral ribonucleoprotein complexes outside the capsid lattice, which led to premature degradation of the viral genome and IN in target cells. Collectively, our studies uncover causal mechanisms for the class II phenotype and highlight an essential role of IN-RNA interactions for accurate virion maturation.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files.

Article and author information

Author details

  1. Jennifer L Elliott

    Department of Molecular Microbiology, Washington University School of Medicine, Saint Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Jenna Eve Eschbach

    Department of Molecular Microbiology, Washington University School of Medicine, Saint Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Pratibha C Koneru

    Division of Infectious Diseases, University of Colorado School of Medicine, Aurora, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3955-4548
  4. Wen Li

    Dana-Farber Cancer Institute, Department of Cancer Immunology and Virology, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Maritza Puray Chavez

    Department of Molecular Microbiology, Washington University School of Medicine, Saint Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Dana Townsend

    Department of Molecular Microbiology, Washington University School of Medicine, Saint Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Dana Q Lawson

    Department of Molecular Microbiology, Washington University School of Medicine, Saint Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Alan N Engelman

    Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Mamuka Kvaratskhelia

    Division of Infectious Diseases, University of Colorado School of Medicine, Aurora, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3800-0033
  10. Sebla Bulent Kutluay

    Department of Molecular Microbiology, Washington University School of Medicine, Saint Louis, United States
    For correspondence
    kutluay@wustl.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5549-7032

Funding

National Institutes of Health (GM103297)

  • Sebla Bulent Kutluay

National Institutes of Health (GM122458)

  • Sebla Bulent Kutluay

National Institutes of Health (AI143389)

  • Jennifer L Elliott

National Institutes of Health (AI062520)

  • Mamuka Kvaratskhelia
  • Sebla Bulent Kutluay

National Institutes of Health (AI150472)

  • Mamuka Kvaratskhelia

National Institutes of Health (AI070042)

  • Alan N Engelman

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Viviana Simon, Icahn School of Medicine at Mount Sinai, United States

Version history

  1. Received: December 10, 2019
  2. Accepted: September 22, 2020
  3. Accepted Manuscript published: September 22, 2020 (version 1)
  4. Version of Record published: November 17, 2020 (version 2)

Copyright

© 2020, Elliott et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,914
    views
  • 324
    downloads
  • 28
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Jennifer L Elliott
  2. Jenna Eve Eschbach
  3. Pratibha C Koneru
  4. Wen Li
  5. Maritza Puray Chavez
  6. Dana Townsend
  7. Dana Q Lawson
  8. Alan N Engelman
  9. Mamuka Kvaratskhelia
  10. Sebla Bulent Kutluay
(2020)
Integrase-RNA interactions underscore the critical role of integrase in HIV-1 virion morphogenesis
eLife 9:e54311.
https://doi.org/10.7554/eLife.54311

Share this article

https://doi.org/10.7554/eLife.54311

Further reading

    1. Microbiology and Infectious Disease
    Michael D Sacco, Lauren R Hammond ... Yu Chen
    Research Article

    In the Firmicutes phylum, GpsB is a membrane associated protein that coordinates peptidoglycan synthesis with cell growth and division. Although GpsB has been studied in several bacteria, the structure, function, and interactome of Staphylococcus aureus GpsB is largely uncharacterized. To address this knowledge gap, we solved the crystal structure of the N-terminal domain of S. aureus GpsB, which adopts an atypical, asymmetric dimer, and demonstrates major conformational flexibility that can be mapped to a hinge region formed by a three-residue insertion exclusive to Staphylococci. When this three-residue insertion is excised, its thermal stability increases, and the mutant no longer produces a previously reported lethal phenotype when overexpressed in Bacillus subtilis. In S. aureus, we show that these hinge mutants are less functional and speculate that the conformational flexibility imparted by the hinge region may serve as a dynamic switch to finetune the function of the GpsB complex and/or to promote interaction with its various partners. Furthermore, we provide the first biochemical, biophysical, and crystallographic evidence that the N-terminal domain of GpsB binds not only PBP4, but also FtsZ, through a conserved recognition motif located on their C-termini, thus coupling peptidoglycan synthesis to cell division. Taken together, the unique structure of S. aureus GpsB and its direct interaction with FtsZ/PBP4 provide deeper insight into the central role of GpsB in S. aureus cell division.

    1. Microbiology and Infectious Disease
    Moagi Tube Shaku, Peter K Um ... Bavesh D Kana
    Research Article

    Mechanisms by which Mycobacterium tuberculosis (Mtb) evades pathogen recognition receptor activation during infection may offer insights for the development of improved tuberculosis (TB) vaccines. Whilst Mtb elicits NOD-2 activation through host recognition of its peptidoglycan-derived muramyl dipeptide (MDP), it masks the endogenous NOD-1 ligand through amidation of glutamate at the second position in peptidoglycan side-chains. As the current BCG vaccine is derived from pathogenic mycobacteria, a similar situation prevails. To alleviate this masking ability and to potentially improve efficacy of the BCG vaccine, we used CRISPRi to inhibit expression of the essential enzyme pair, MurT-GatD, implicated in amidation of peptidoglycan side-chains. We demonstrate that depletion of these enzymes results in reduced growth, cell wall defects, increased susceptibility to antibiotics, altered spatial localization of new peptidoglycan and increased NOD-1 expression in macrophages. In cell culture experiments, training of a human monocyte cell line with this recombinant BCG yielded improved control of Mtb growth. In the murine model of TB infection, we demonstrate that depletion of MurT-GatD in BCG, which is expected to unmask the D-glutamate diaminopimelate (iE-DAP) NOD-1 ligand, yields superior prevention of TB disease compared to the standard BCG vaccine. In vitro and in vivo experiments in this study demonstrate the feasibility of gene regulation platforms such as CRISPRi to alter antigen presentation in BCG in a bespoke manner that tunes immunity towards more effective protection against TB disease.